NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $1.81
▼
$2.24
52-Week Range: N/A

Volume: 2,579 shs
Average Volume: 162,968 shs
Market Capitalization: $8.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Financials Institutional Ownership Options Chain SEC Filings Short Interest Social Media

About Rexahn Pharmaceuticals (NASDAQ:REXN) Stock

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

March 27, 2023 | benzinga.com

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

January 1, 2023 | thestreet.com

Rexahn: Holes Galore in Serdaxin Data

September 30, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

November 18, 2020 | reuters.com

Ocuphire Pharma Inc

November 10, 2020 | finance.yahoo.com

Ocuphire to Participate in Upcoming Virtual HCW Conference in November

November 7, 2020 | apnews.com

Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger ...

November 5, 2020 | feeds.benzinga.com

Ocuphire Pharma Completes Transactions and Begins Trading on Nasdaq as OCUP

November 5, 2020 | finance.yahoo.com

Rexahn Pharmaceuticals Announces Expected Effectiveness of Reverse Stock Split and Merger Transaction with Ocuphire Pharma

September 30, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

November 3, 2020 | apnews.com

Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with ...

November 2, 2020 | finance.yahoo.com

Rexahn Pharmaceuticals Announces Stockholder Approval of All Proposals Required for Merger with Ocuphire Pharma

October 24, 2020 | nasdaq.com

Rexahn Pharmaceuticals, Inc. Common Stock (REXN)

September 24, 2020 | uk.finance.yahoo.com

Rexahn Pharmaceuticals, Inc. (R3X.F)

August 19, 2020 | sg.finance.yahoo.com

REXAHN PHARMAC. DL -,0001 (R3X.BE)

August 14, 2020 | prnewswire.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds REXN and TORC Shareholders About Its Ongoing Investigations

July 31, 2020 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds DLMV and REXN Shareholders About Its Ongoing Investigations

July 21, 2020 | finance.yahoo.com

Lifshitz Law Firm, P.C. Announces Investigation of Benefytt Technologies, Inc., Noble Energy, Inc., Maxim Integrated Products and Rexahn Pharmaceuticals, Inc.

July 17, 2020 | finance.yahoo.com

INVESTIGATION ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm

July 15, 2020 | finance.yahoo.com

NOTICE - IMPORTANT SHAREHOLDER INVESTIGATION UPDATE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: Pure Acquisition Corp. (NasdaqGS - PACQ), Fortress Value Acquisition Corp. (NYSE - FVAC), Rexahn Pharmaceuticals, Inc. (Nasdaq - REXN)

July 14, 2020 | finance.yahoo.com

INVESTIGATION ALERT: Halper Sadeh LLP is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - GARS, NVTA, REXN

July 8, 2020 | finance.yahoo.com

ALERT: Halper Sadeh LLP Continues to Investigate Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - DCOM, REXN, MYOS

July 7, 2020 | finance.yahoo.com

INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of Rexahn Pharmaceuticals, Inc.- REXN

July 7, 2020 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Reminds REXN and DLMV Shareholders About Its Ongoing Investigations

July 3, 2020 | finance.yahoo.com

LEGAL INVESTIGATION ALERT: Halper Sadeh LLP Announces It is Investigating Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MYOS, REXN

July 1, 2020 | finance.yahoo.com

REXAHN PARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Rexahn Pharmaceuticals, Inc. - REXN

July 1, 2020 | www.businesswire.com

REXAHN PARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Rexahn Pharmaceuticals, Inc. - REXN

June 29, 2020 | finance.yahoo.com

Rexahn Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Merger Of Rexahn Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm

See More Headlines

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REXN Company Calendar

Last Earnings: 8/07/2019
Today: 9/29/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:REXN
CUSIP: N/A
CIK: 1228627
Web: www.rexahn.com
Phone: (248) 681-9815
Fax: N/A
Employees: 5
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,640,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -72.60%
Return on Assets: -55.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.37
Quick Ratio: 3.37

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.48 per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,483,000
Free Float: N/A
Market Cap: $8.11 million
Optionable: Optionable
Beta: 0.98

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mina Patel Sooch
President, Chief Executive Officer & Director

Bernhard Hoffmann
Vice President-Corporate Development & Operations

Amy Rabourn
Chief Accounting Officer & Vice President-Finance

Konstantinos Charizanis
Senior Director-Market Strategy, R&D

Drey Coleman
Director-Clinical Operations & Vendor Management

Key Competitors

View All Competitors

REXN Stock - Frequently Asked Questions

How were Rexahn Pharmaceuticals' earnings last quarter?: Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) issued its earnings results on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.34.
When did Rexahn Pharmaceuticals' stock split?: Rexahn Pharmaceuticals shares reverse split before market open on Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Rexahn Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Imunon (CLSN), LadRx (CYTR) and SCYNEXIS (SCYX).
What is Rexahn Pharmaceuticals' stock symbol?: Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."
How much money does Rexahn Pharmaceuticals make?: Rexahn Pharmaceuticals (NASDAQ:REXN) has a market capitalization of $0.00.
How can I contact Rexahn Pharmaceuticals?: Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The official website for the company is www.rexahn.com. The company can be reached via phone at (248) 681-9815 or via email at jurchisons@rexahn.com.

This page (NASDAQ:REXN) was last updated on 9/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Rexahn Pharmaceuticals (REXN) Stock Forecast, Price & News

About Rexahn Pharmaceuticals (NASDAQ:REXN) Stock

REXN Stock News Headlines

REXN Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

REXN Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info